Ascentage Pharma reports 81% surge in Olverembatinib sales amid global Phase III expansion
Ascentage Pharma (NASDAQ:AAPG), a global biopharmaceutical company developing novel therapies for cancers, hepatitis B virus, and age-related diseases, announced its unaudited financial results for the year ended December 31, 2025.










